Pharma BD Deal Intelligence
The Organon afterthought that Merck barely noticed became pharma's biggest jackpot: pembrolizumab (Keytruda) turned into the best-selling drug in history, bailing out a $41.1B deal whose headline rationale—Remicade, Zetia/Vytorin, a "five-star" pipeline of golimumab, Saphris, Bridion, vorapaxar, and boceprevir—mostly cratered, with Zetia/Vytorin sales dropping ~40% in 2017 alone after patent expiry.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Merck and Schering-Plough announced a definitive merger agreement valued at $41.1 billion structured as a reverse merger to preserve joint venture rights to…
The deal will result in billions in annual savings for the merged entity, with expected annual cost reductions of $3.5 billion and expanded geographic reach…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Merck acquired Schering-Plough in a $41.1 billion reverse merger, gaining a diversified portfolio including Remicade, Nasonex, and the Vytorin/Zetia cholesterol franchise, creating the second-largest pharmaceutical company globally at the time.
73M US cases/yr · $15.0B Global Cholesterol Market (2009)
Vytorin/Zetia franchise was the Merck/SP JV's largest asset. Zetia first-in-class cholesterol absorption inhibitor.
ENHANCE controversy damaged Vytorin; IMPROVE-IT validated ezetimibe. Both went generic. Ezetimibe remains SOC add-on.
50M US cases/yr · $8.0B Global Allergic Rhinitis (2009)
Nasonex was SP's blockbuster intranasal steroid. Combined with Merck's Singulair for dominant allergy portfolio.
Nasonex + Singulair = two allergy blockbusters. Clarinex added OTC potential. Generic competition within years.
1.5M US cases/yr · $25.0B Global Anti-TNF Market (2009)
Merck acquired Schering-Plough for $41.1B in 2009, doubling late-stage pipeline. Remicade (shared with J&J) at $5.3B global revenue was the crown jewel.
Remicade competed with Humira and Enbrel. Biosimilar erosion post-2017.
24K US cases/yr · $3.0B Global Temodar + HCV (2009)
Temodar was SOC for glioblastoma. PegIntron leading HCV treatment before DAAs.
Temodar generic 2013. PegIntron displaced by DAAs (Sovaldi/Harvoni) 2014.
Merck and Schering-Plough announce $41.1B merger agreement. Schering-Plough shareholders to receive $10.50 cash plus 0.5767 Merck shares per share.
Merck shareholders vote to approve the Schering-Plough merger at a special meeting, with strong majority support for the combination.
FTC approves merger conditioned on Merck divesting its 50% Merial stake to Sanofi-Aventis (animal health) and Schering-Plough selling rolapitant assets to Opko Health.
Merck and Schering-Plough complete their reverse merger, with Schering-Plough technically acquiring Merck but retaining the Merck name. Creates diversified pharma giant.
Merck reports full-year 2010 worldwide sales of $46.0B, reflecting the first full year of the Schering-Plough combination including Remicade, Vytorin, and Zetia franchises.
Merck's combined R&D engine yields pembrolizumab (Keytruda), which would become the world's best-selling drug. Validates the scientific rationale behind the Schering-Plough merger.
Despite near-term revenue declines from patent cliffs (Vytorin, Remicade biosimilars), the merger's R&D pipeline produced Keytruda -- one of pharma's most successful M&A bets.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Schering-Plough Corp. (this deal) | 2009 | $41.1B | 69 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2009 deals · Merck & Co. Inc. deals · Cardiovascular deals